Physician profile
Thomas O Pearson
NPI 1144204124
$151,112.05
in general payments reported to CMS, 2019-2025
40 companies · $15K in 2025
The $15K reported for 2025 was more than what 91% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,249 · 2020: $17K · 2021: $49K · 2022: $29K · 2023: $32K · 2024: $7,762 · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $42K · Honoraria: $4,620 · Food and Beverage: $4,075 · Travel and Lodging: $3,259 · Consulting Fee: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $42,376.25 |
| Honoraria | $4,620.00 |
| Food and Beverage | $4,074.61 |
| Travel and Lodging | $3,259.45 |
| Consulting Fee | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $117,236.60 | 2020-2025 | |
| Allergan, INC. | $19,931.87 | 2020-2021 | |
| Mdd US Operations, LLC | $6,167.80 | 2022-2025 | |
| Idorsia Pharmaceuticals US INC | $1,496.79 | 2023 | Quviviq |
| Pfizer INC. | $502.83 | 2019-2025 | |
| Neurocrine Biosciences, INC. | $465.50 | 2021-2024 | Ingrezza, Ongentys |
| Eisai INC. | $455.92 | 2020-2023 | |
| Sunovion Pharmaceuticals INC. | $440.78 | 2019-2022 | |
| Lilly USA, LLC | $422.18 | 2019-2024 | Reyvow, Emgality, Amyvid |
| Jazz Pharmaceuticals INC. | $379.07 | 2019-2025 | |
| Amgen INC. | $340.91 | 2019-2023 | Aimovig |
| Teva Pharmaceuticals USA, INC. | $299.13 | 2019-2024 | Ajovy, Austedo Xr |
| Neuronetics, INC. | $285.00 | 2019-2022 | |
| Lundbeck LLC | $263.85 | 2020-2025 | Rexulti |
| Biohaven Pharmaceuticals, INC. | $259.52 | 2020-2021 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Pearson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.